<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768569</url>
  </required_header>
  <id_info>
    <org_study_id>PINIHL-AET</org_study_id>
    <nct_id>NCT04768569</nct_id>
  </id_info>
  <brief_title>Noise-Induced Hearing Loss-Acute Exposure Treatment</brief_title>
  <acronym>PINIHL-AET</acronym>
  <official_title>Pharmaceutical Interventions for Noise-Induced Hearing Loss-Acute Exposure Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Akron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gateway Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of zonisamide for the&#xD;
      treatment of noise-induced hearing loss in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded placebo-control trial with three parallel groups,&#xD;
      to make use of a common control group. After being informed about the study expectations and&#xD;
      potential risks, all individuals providing written informed consent will undergo screening to&#xD;
      determine eligibility for study entry.&#xD;
&#xD;
      Participants who meet the eligibility requirements will be randomized in a balanced fashion&#xD;
      into one of 3 arms:&#xD;
&#xD;
      Group 1) Zonisamide 100 milligrams (mg) pre-op + Placebo post-op; Group 2) Placebo pre- +&#xD;
      placebo post-op; and Group 3) Zonisamide 100 mg post-op + placebo post-op&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized, double-blinded placebo-control trial with three parallel groups, to make use of a common control group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects will be randomized in a balanced fashion into one of 3 arms: Zonisamide 100 mg pre-op, Placebo, or Zonisamide 100 mg post-op.&#xD;
To ensure double-blinding of the trial, each subject will be assigned a previously prepared envelope with one package labeled &quot;1&quot; and designated to be taken 4 hours prior to surgery and another package labeled &quot;2&quot; designated to be taken within 4-12 hours after surgery or when the patient is released clinically to oral medication.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of PTS-positive subjects</measure>
    <time_frame>30 days</time_frame>
    <description>The primary efficacy endpoint will be the proportion of PTS-positive subjects defined as the ratio of PTS-positive subjects to total number of subjects within each study arm/group. Subjects defined as PTS-positive will demonstrate an increase in threshold that is ≥10 dB HL at any frequency from 2-6 kHz post-surgery as compared to baseline audiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of distortion product otoacoustic emissions (DPOAE) shift</measure>
    <time_frame>30 days</time_frame>
    <description>The secondary efficacy outcome measures will be the rate of temporary cochlear change as measured by a DPOAE amplitude shift at any frequency that is significantly greater than the stability of each measurement (i.e., 95% confidence interval of each measurement do not overlap). The rate of DPOAE shift is the ratio of DPOAE shift-positive subjects to total subjects within each arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hearing Loss, Noise-Induced</condition>
  <arm_group>
    <arm_group_label>Zonisamide Pre-op + Placebo Post-op</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For subjects randomized to zonisamide pre-op, the pre-op package will contain one zonisamide capsule (100 mg PO) and the post-op package will contain one placebo capsule that looks, smells, and tastes the same as zonisamide capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pre-op + Placebo Post-op</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the subjects randomized to placebo, both pre- and post-op packages will contain placebo capsules that looks, smells, and taste the same as zonisamide capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pre-op + Zonisamide Post-op</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For subjects randomized to zonisamide post-op, the pre-op package will contain one placebo capsule and the post-op package will contain one zonisamide capsule (100 mg PO).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide 100Mg Cap</intervention_name>
    <description>ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.</description>
    <arm_group_label>Placebo Pre-op + Zonisamide Post-op</arm_group_label>
    <arm_group_label>Zonisamide Pre-op + Placebo Post-op</arm_group_label>
    <other_name>Zonegran</other_name>
    <other_name>ZNS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.</description>
    <arm_group_label>Placebo Pre-op + Placebo Post-op</arm_group_label>
    <arm_group_label>Placebo Pre-op + Zonisamide Post-op</arm_group_label>
    <arm_group_label>Zonisamide Pre-op + Placebo Post-op</arm_group_label>
    <other_name>microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo a skull-based surgery that requires at least 1-hour of&#xD;
             surgical-drilling&#xD;
&#xD;
          -  Air conduction thresholds in the non-operated ears are no worse than 25 decibel (dB)&#xD;
             hearing loss (HL) from 0.5 to 3 kilohertz (kHz), no worse than 30dB HL at 4kHz, and no&#xD;
             worse than 45dB HL at 6 and 8 kHz at screening&#xD;
&#xD;
          -  Observed air-bone gap &lt; 10 dB HL at 0.5, 1, 2, and 4 kHz, with normal tympanometry&#xD;
&#xD;
          -  Ability to understand and willingness to sign an Institutional Review Board (IRB)&#xD;
             approved written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of known sulfa allergy or hypersensitivity to carbonic anhydrase inhibitors&#xD;
&#xD;
          -  History of moderate-to-severe kidney or liver disease&#xD;
&#xD;
          -  Acute viral, bacterial, fungal or parasitic infection&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Currently pregnant or breast-feeding&#xD;
&#xD;
          -  Any current or history of ear disorder and/or central auditory dysfunction in the&#xD;
             non-operated ear&#xD;
&#xD;
          -  History of ototoxic drug use&#xD;
&#xD;
          -  Current use of strong/moderate 3A4 inhibitor/inducer and grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A Buchman, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Banan Ead</last_name>
    <phone>314-454-2197</phone>
    <email>eadbanan@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Kukuljan</last_name>
    <phone>314-362-7563</phone>
    <email>kukuljas@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Banan Ead</last_name>
      <phone>314-454-2197</phone>
      <email>eadbanan@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Craig A Buchman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Noise-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

